Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 12/2007

01-12-2007 | Case Report

Pericarditis: a rare complication of methotrexate therapy

Authors: Tayyab Mohyuddin, Mazen Elyan, Irving Kushner

Published in: Clinical Rheumatology | Issue 12/2007

Login to get access

Abstract

Serositis is a rare complication of methotrexate (MTX) administration. We report a 60-year-old man with rheumatoid arthritis who developed pericarditis after taking his weekly MTX dose, which recurred within hours after 2 subsequent weekly MTX doses. Pericarditis has not recurred after discontinuance of MTX over 3 years ago. We conclude that he had MTX-induced pericarditis, based on the close temporal relationship between MTX ingestion and manifestations of pericarditis on three distinct occasions because of the previous reports of MTX-induced pericarditis and because pericarditis has not recurred after MTX withdrawal.
Literature
1.
Sharma S, Jagdev S, Coleman RE, Hancock BW, Lorigan PC (1999) Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. Br J Cancer 81:1037–1041CrossRefPubMedPubMedCentral
2.
Palungwachira P, Palungwachira P, Laohathai P (1998) Methotrexate induced pericarditis and pericardial effusion in psoriatic patient. J Med Assoc Thai 81:141–145PubMed
3.
Forbat LN, Hancock BW, Gershlick AH (1995) Methotrexate-induced pericarditis and pericardial effusion; first reported case. Postgrad Med J 71:244–245CrossRefPubMedPubMedCentral
4.
Combe B, Didry C, Gutierrez M, Anaya JM, Sany J (1993) Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med 2:153–156PubMed
5.
Racaud O (1994) Extra-articular manifestations of rheumatoid arthritis at the time of basic methotrexate treatment: apropos of a case of nodulosis with pericarditis. Rev Med Suisse Romande 114:343–344
6.
Akoun GM, Gauthier-Rahman S, Mayaud CM, Touboul JL, Denis MF (1987) Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 91:96–99CrossRefPubMed
7.
White DA, Rankin JA, Stover DE, Gellene RA, Gupta S (1989) Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 139:18–21CrossRefPubMed
Metadata
Title
Pericarditis: a rare complication of methotrexate therapy
Authors
Tayyab Mohyuddin
Mazen Elyan
Irving Kushner
Publication date
01-12-2007
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0630-1

Other articles of this Issue 12/2007

Clinical Rheumatology 12/2007 Go to the issue

Original Article

Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus

Case Report

Steady improvement of prothrombin levels after cyclophosphamide therapy in pediatric lupus anticoagulant hypoprothrombinemia syndrome (LAHPS)

Original Article

Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?

Brief Report

Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis

CaseReport

Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment

Original Article

High positivity of anti-CCP antibodies in patients with Down syndrome
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits